Method for determining physiological effects of hemoglobin
CA 2680378 C · Owner: Singel, David J. · Inventors: Gow, Andrew J.; Singel, David J.; Stamler, Jonathan S.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
NO preferentially binds to the minor population of the hemoglobin's vacant hemes in a copperative manner, nitrosylates hemoglobin thiols or reacts with , liberated superoxide in solution. The distribution of minor forms of hemoglobin can , be tested and the results can be used to predict whether a composition of hemoglobin , will scavenge, load, eliminate or donate NO. Hemoglobin thus serves to regulate the , chemistry of NO. SNO-hemoglobin transfers NO equivalents to the red blood cell anion transport protein AE1, which serves to export NO from red blood cells. Regulation of AE1 function is the basis for methods of therapy to affect levels of NO , or its biological equivalent.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 2, 2000 and granted September 24, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 2, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 2, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.